Lifeward Ltd. filings document regulatory disclosures for a Nasdaq-listed medical technology company whose ordinary shares trade under LFWD. The filing record includes Form 8-K material-event reports, annual-report references, shareholder vote results, and disclosures tied to its rehabilitation and recovery technology business.
Recent filings cover a completed acquisition, related ordinary-share and warrant consideration, a reverse share split, amendments to articles of association, authorized share-capital changes, and Nasdaq listing-compliance matters. The filings also document board and audit committee governance, officer employment and compensation arrangements, operating and financial results, material agreements, risk factors, and clinical or regulatory disclosures.
Lifeward Ltd. (LFWD) seeks votes at its October 30, 2026 annual and extraordinary meeting on nine proposals covering director elections, external-director and director compensation, Interim CEO Josh Hexter’s compensation, issuance of ordinary shares above the exchange cap upon conversion or exercise of certain securities, a three-year compensation-policy renewal, auditor reappointment, executive pay and future say-on-pay frequency. The Board recommends “FOR” Proposals 1–8 and “EVERY YEAR” for Proposal 9; shareholders of record on September 30, 2026 may vote.
Proposals 2, 3, 4 and 6 also require a “Special Majority” under Israeli law: in addition to an ordinary majority, either a majority of eligible votes cast must support the proposal or opposing votes by non-controlling shareholders without a personal interest must not exceed 2% of outstanding voting power. For 2025, Lifeward says revenue and net-income targets were not achieved, so no bonus was paid for those corporate goals; individual-goal bonuses were $22,050 for CFO Almog Adar and $6,329 for former VP Jeannine Lynch. Former CEO Mark Grant received a guaranteed $177,625 bonus.
Lifeward Ltd. (LFWD) is asking shareholders to vote at its 2026 Annual and Extraordinary General Meeting on October 30, 2026 in Tel Aviv on nine proposals covering board composition, compensation, auditor ratification and share issuance authorities. Shareholders will vote on re-electing two Class III directors, electing a new External Director, approving director and CEO compensation, and authorizing issuance of ordinary shares above the Nasdaq exchange cap upon conversion or exercise of certain outstanding securities. The agenda also includes renewal of the three‑year compensation policy for officers and directors, re‑appointment of Ernst & Young member Kost Forer Gabbay & Kasierer as auditor, a non‑binding Say‑on‑Pay vote and a vote on the frequency of future Say‑on‑Pay votes. The board recommends voting FOR Proposals 1‑8 and EVERY YEAR on Proposal 9. Oramed Pharmaceuticals Inc., which became a controlling shareholder through the Oratech acquisition, holds 44.2% of Lifeward’s outstanding voting power.
Lifeward Ltd. (LFWD) announces that its 2026 Annual and Extraordinary General Meeting of Shareholders will be held on October 30, 2026. Because this date is more than 30 days after the prior year’s annual meeting anniversary, shareholders seeking to include proposals in the company’s proxy materials under Rule 14a-8 must ensure their proposals are received at the company’s Israeli office by September 23, 2026. Proposals and director nominations must also comply with SEC rules, the Israel Companies Law 5759-1999, and Lifeward’s Articles of Association.
Lifeward Ltd. (symbol: LFWD) is the issuer of record for a Form 4 filing submitted to the SEC. Zamir Haggai reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. (LFWD) reported that director Zamir Haggai received an equity award of 6,711 ordinary shares on August 14, 2026. The award represents restricted stock units granted under Lifeward’s 2025 Incentive Compensation Plan and was reported at a per-share price of $0.00 as a compensation grant.
The 6,711 RSUs vest ratably in four equal quarterly installments starting on the August 14, 2026 grant date, and Haggai’s directly held reported position after the grant is 6,711 ordinary shares, reflecting this new award.
Lifeward Ltd. (LFWD) had a Form 3 filed for director Zamir Haggai, serving as an initial statement of beneficial ownership. The filing reports no equity transactions, derivative positions, or current holdings for him, and references an attached Power of Attorney as Exhibit 24.1.
Lifeward Ltd. (LFWD) released an investor presentation outlining its strategy as a restorative healthcare platform focused on robotic exoskeletons and rehabilitation technologies, supported by what it describes as an established reimbursement infrastructure. The company reports last-twelve-month revenue of $21.8 million as of June 30, 2026 and $6.6 million in second-quarter 2026 revenue, up 15% year over year, with a 42% gross margin and a pro forma cash position of $10.9 million.
The presentation highlights a portfolio including the ReWalk powered exoskeleton, AlterG anti-gravity rehab systems, and an upper-extremity exoskeleton in development, plus a connected data platform and multiple pipeline products targeted for 2027–2031, each subject to regulatory clearance. Lifeward emphasizes reimbursement “moat” elements: HCPCS code K1007, an established Medicare Fee Schedule rate of $95,081, and estimated coverage for about 46% of Medicare Advantage enrollees. A strategic partnership with Oramed Pharmaceuticals could provide up to $47 million in milestone-based funding and gives Lifeward economic exposure to Oramed’s Protein Oral Delivery (POD) platform and oral insulin candidate ORMD-0801, while Oramed oversees development.
Lifeward Ltd. (LFWD) reported an initial insider ownership filing for Joshua Hexter, identified as Interim CEO. The Form 3 states in the remarks that no securities are beneficially owned by the reporting person as of this filing. No transactions or derivative positions are listed.
Lifeward Ltd. (LFWD) announced leadership changes effective in late 2026. On August 31, 2026, President and Chief Executive Officer Mark Grant departed his roles, including his Board seat, under a Separation Agreement. He will serve as Senior Advisor through September 30, 2026 for a $40,000 consulting fee, with all unvested equity awards forfeiting as of August 31, 2026 and no cash severance or extended benefits beyond accrued compensation.
The Board appointed Josh Hexter, age 56, as Interim Chief Executive Officer and principal executive officer effective September 1, 2026, under an employment agreement providing a gross monthly base salary of NIS 100,000 plus a NIS 5,000 commuting allowance or a company car and an annual bonus eligibility. Hexter will substantially reduce his responsibilities at controlling shareholder Oramed Pharmaceuticals Inc. The Board also appointed Rami Aviram, age 47, as Chief Financial Officer, principal financial officer and principal accounting officer effective November 1, 2026, with a gross monthly base salary of NIS 70,000 and a NIS 5,000 commuting allowance or a company car, along with customary Israeli-law benefits and bonus eligibility.
Lifeward Ltd. (symbol: LFWD) is the issuer of record for a Form 4 filing submitted to the SEC.